Literature DB >> 30289454

Dusp6 is a genetic modifier of growth through enhanced ERK activity.

Andy H Vo1, Kayleigh A Swaggart2, Anna Woo3, Quan Q Gao3, Alexis R Demonbreun3, Katherine S Fallon3, Mattia Quattrocelli3, Michele Hadhazy3, Patrick G T Page3, Zugen Chen4, Ascia Eskin4, Kevin Squire4, Stanley F Nelson4, Elizabeth M McNally3.   

Abstract

Like other single-gene disorders, muscular dystrophy displays a range of phenotypic heterogeneity even with the same primary mutation. Identifying genetic modifiers capable of altering the course of muscular dystrophy is one approach to deciphering gene-gene interactions that can be exploited for therapy development. To this end, we used an intercross strategy in mice to map modifiers of muscular dystrophy. We interrogated genes of interest in an interval on mouse chromosome 10 associated with body mass in muscular dystrophy as skeletal muscle contributes significantly to total body mass. Using whole-genome sequencing of the two parental mouse strains combined with deep RNA sequencing, we identified the Met62Ile substitution in the dual-specificity phosphatase 6 (Dusp6) gene from the DBA/2 J (D2) mouse strain. DUSP6 is a broadly expressed dual-specificity phosphatase protein, which binds and dephosphorylates extracellular-signal-regulated kinase (ERK), leading to decreased ERK activity. We found that the Met62Ile substitution reduced the interaction between DUSP6 and ERK resulting in increased ERK phosphorylation and ERK activity. In dystrophic muscle, DUSP6 Met62Ile is strongly upregulated to counteract its reduced activity. We found that myoblasts from the D2 background were insensitive to a specific small molecule inhibitor of DUSP6, while myoblasts expressing the canonical DUSP6 displayed enhanced proliferation after exposure to DUSP6 inhibition. These data identify DUSP6 as an important regulator of ERK activity in the setting of muscle growth and muscular dystrophy.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30289454      PMCID: PMC6322066          DOI: 10.1093/hmg/ddy349

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  51 in total

Review 1.  The MEK/ERK cascade: from signaling specificity to diverse functions.

Authors:  Yoav D Shaul; Rony Seger
Journal:  Biochim Biophys Acta       Date:  2006-10-19

2.  Mapping ERK2-MKP3 binding interfaces by hydrogen/deuterium exchange mass spectrometry.

Authors:  Bo Zhou; Jialin Zhang; Sijiu Liu; Sharanya Reddy; Fang Wang; Zhong-Yin Zhang
Journal:  J Biol Chem       Date:  2006-10-17       Impact factor: 5.157

3.  Solution structure of ERK2 binding domain of MAPK phosphatase MKP-3: structural insights into MKP-3 activation by ERK2.

Authors:  A Farooq; G Chaturvedi; S Mujtaba; O Plotnikova; L Zeng; C Dhalluin; R Ashton; M M Zhou
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

4.  Dusp6 attenuates Ras/MAPK signaling to limit zebrafish heart regeneration.

Authors:  Maria A Missinato; Manush Saydmohammed; Daniel A Zuppo; Krithika S Rao; Graham W Opie; Bernhard Kühn; Michael Tsang
Journal:  Development       Date:  2018-03-06       Impact factor: 6.868

5.  DUSP6/MKP-3 inactivates ERK1/2 but fails to bind and inactivate ERK5.

Authors:  Rebecca S Arkell; Robin J Dickinson; Matthew Squires; Shaista Hayat; Stephen M Keyse; Simon J Cook
Journal:  Cell Signal       Date:  2007-12-27       Impact factor: 4.315

6.  Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial.

Authors:  Craig Campbell; Hugh J McMillan; Jean K Mah; Mark Tarnopolsky; Kathryn Selby; Ty McClure; Dawn M Wilson; Matthew L Sherman; Diana Escolar; Kenneth M Attie
Journal:  Muscle Nerve       Date:  2016-12-23       Impact factor: 3.217

7.  Effect of genetic background on the dystrophic phenotype in mdx mice.

Authors:  William D Coley; Laurent Bogdanik; Maria Candida Vila; Qing Yu; Jack H Van Der Meulen; Sree Rayavarapu; James S Novak; Marie Nearing; James L Quinn; Allison Saunders; Connor Dolan; Whitney Andrews; Catherine Lammert; Andrew Austin; Terence A Partridge; Gregory A Cox; Cathleen Lutz; Kanneboyina Nagaraju
Journal:  Hum Mol Genet       Date:  2015-11-12       Impact factor: 6.150

8.  QTLRel: an R package for genome-wide association studies in which relatedness is a concern.

Authors:  Riyan Cheng; Mark Abney; Abraham A Palmer; Andrew D Skol
Journal:  BMC Genet       Date:  2011-07-27       Impact factor: 2.797

9.  Mouse Phenome Database: an integrative database and analysis suite for curated empirical phenotype data from laboratory mice.

Authors:  Molly A Bogue; Stephen C Grubb; David O Walton; Vivek M Philip; Georgi Kolishovski; Tim Stearns; Matthew H Dunn; Daniel A Skelly; Beena Kadakkuzha; Gregg TeHennepe; Govindarajan Kunde-Ramamoorthy; Elissa J Chesler
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971

10.  Beta-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex.

Authors:  C G Bönnemann; R Modi; S Noguchi; Y Mizuno; M Yoshida; E Gussoni; E M McNally; D J Duggan; C Angelini; E P Hoffman
Journal:  Nat Genet       Date:  1995-11       Impact factor: 38.330

View more
  3 in total

Review 1.  The ties that bind: functional clusters in limb-girdle muscular dystrophy.

Authors:  Elisabeth R Barton; Christina A Pacak; Whitney L Stoppel; Peter B Kang
Journal:  Skelet Muscle       Date:  2020-07-29       Impact factor: 4.912

2.  ERK1/2 signaling induces skeletal muscle slow fiber-type switching and reduces muscular dystrophy disease severity.

Authors:  Justin G Boyer; Vikram Prasad; Taejeong Song; Donghoon Lee; Xing Fu; Kelly M Grimes; Michelle A Sargent; Sakthivel Sadayappan; Jeffery D Molkentin
Journal:  JCI Insight       Date:  2019-04-09

3.  DUSP6 protects murine podocytes from high glucose‑induced inflammation and apoptosis.

Authors:  Liqiang Chen; Yaokun Wang; Haiyan Luan; Guangyu Ma; Huiming Zhang; Guang Chen
Journal:  Mol Med Rep       Date:  2020-07-09       Impact factor: 2.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.